Oncology · Medical Literature
Superiority of Adjuvant Hyperfractionated Radiotherapy Over Chemotherapy Following Radical Cystectomy.
Abstract
Bladder cancer (LABC) after radical cystectomy (RC) is common, even with chemotherapy, and is associated with high morbidity and mortality. Therefore, this work aimed to investigate the effect and efficacy of adjuvant sandwich chemotherapy plus radiotherapy versus adjuvant chemotherapy alone for LABC after RC. This phase III trial was conducted in 125 patients with bladder cancer who underwent RC and were randomized to one of the following two adjuvant treatments. The chemotherapy plus RT arm received 2 cycles of gemcitabine and cisplatin before and after RT, with a 1-week break between chemotherapy and RT. The second arm, receiving chemotherapy alone, had 4 cycles of gemcitabine and cisplatin. LRF was significantly reduced in the combined group (P < 0.001); however, DM was comparable between groups (p = 0.3). Furthermore, 64.9% of patients in the combined group were still alive, compared with only 5.9% in the chemotherapy group. Moreover, the mean time to local failure was not significantly different between the two groups (24.0 ± 0.1 vs. 26.5 ± 9.8, p = 0.08, respectively, for the combined group compared with the chemotherapy arm), but the mean time to DM was significantly prolonged in the combined group compared with the chemotherapy group (51.2 ± 14.9 vs. 29.7 ± 12.1, p < 0.001, respectively). Adjuvant chemotherapy plus RT was associated with significant improvements in LRFS and improvements in OS compared with chemotherapy alone in LABC.
Clinical relevance
Locoregional failure following radical cystectomy for locally advanced bladder cancer (LABC) remains a significant clinical challenge, with high rates of recurrence and mortality even with adjuvant chemotherapy. This phase III randomized trial addresses the unresolved question of whether adding adjuvant radiotherapy (RT) to gemcitabine-cisplatin chemotherapy improves oncologic outcomes post-cystectomy. Given the limited evidence base for adjuvant strategies in LABC, these findings are directly relevant to urologic oncologists and radiation oncologists managing high-risk post-cystectomy patients.
Key findings
1. Locoregional failure (LRF) was significantly reduced in the combined chemoradiotherapy arm compared to chemotherapy alone (p < 0.001), establishing a clear locoregional control benefit for adjuvant sandwich RT. 2. Overall survival was markedly superior in the combined group, with 64.9% of patients alive versus only 5.9% in the chemotherapy-alone arm — a clinically dramatic difference. 3. Distant metastasis (DM) rates were comparable between groups (p = 0.3), suggesting the RT benefit is primarily locoregional rather than systemic. 4. Mean time to distant metastasis was significantly prolonged in the combined group versus chemotherapy alone (51.2 ± 14.9 vs. 29.7 ± 12.1 months; p < 0.001), despite similar DM rates, indicating delayed systemic progression in the combined arm. 5. Mean time to local failure was not significantly different between the combined and chemotherapy-alone groups (24.0 ± 0.1 vs. 26.5 ± 9.8 months; p = 0.08), though this may reflect limited statistical power or patient numbers. 6. The trial enrolled 125 patients in a phase III randomized design, with the combined arm receiving a sandwich regimen of 2 cycles of gemcitabine-cisplatin pre- and post-RT with a 1-week break, versus 4 cycles of gemcitabine-cisplatin alone.
Practice implications
For patients with LABC who have undergone radical cystectomy and are fit for systemic therapy, clinicians should consider adjuvant sandwich chemoradiotherapy (2 cycles of gemcitabine-cisplatin before and after hyperfractionated RT, with a 1-week interval) over chemotherapy alone, given the substantial locoregional control and overall survival advantages observed. Patient selection should prioritize those at high risk of locoregional recurrence (e.g., pT3/T4, node-positive disease) while carefully evaluating renal function, performance status, and pelvic RT tolerance to minimize morbidity. These findings, if validated in larger multicenter trials, could support updating adjuvant treatment guidelines for LABC to incorporate hyperfractionated RT as a standard component of the post-cystectomy management pathway.